Becker Capital Management’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $845K | Sell |
6,060
-164
| -3% | -$23K | 0.02% | 181 |
|
|
2025
Q4 | $764K | Sell |
6,224
-8
| -0.1% | -$972 | 0.02% | 201 |
|
|
2025
Q3 | $692K | Sell |
6,232
-347
| -5% | -$39.4K | 0.02% | 202 |
|
|
2025
Q2 | $729K | Sell |
6,579
-2,620
| -28% | -$279K | 0.02% | 196 |
|
|
2025
Q1 | $1.03M | Sell |
9,199
-2,130
| -19% | -$220K | 0.03% | 167 |
|
|
2024
Q4 | $1.05M | Sell |
11,329
-5,615
| -33% | -$506K | 0.03% | 159 |
|
|
2024
Q3 | $1.42M | Sell |
16,944
-336
| -2% | -$25.6K | 0.05% | 153 |
|
|
2024
Q2 | $1.19M | Sell |
17,280
-1,840
| -10% | -$123K | 0.04% | 152 |
|
|
2024
Q1 | $1.4M | Sell |
19,120
-2,304
| -11% | -$177K | 0.05% | 144 |
|
|
2023
Q4 | $1.74M | Sell |
21,424
-1,324
| -6% | -$103K | 0.06% | 137 |
|
|
2023
Q3 | $1.7M | Sell |
22,748
-5,974
| -21% | -$459K | 0.07% | 133 |
|
|
2023
Q2 | $2.21M | Sell |
28,722
-8,111
| -22% | -$647K | 0.08% | 123 |
|
|
2023
Q1 | $3.06M | Sell |
36,833
-112,280
| -75% | -$9.3M | 0.12% | 113 |
|
|
2022
Q4 | $12.8M | Sell |
149,113
-108,303
| -42% | -$8.58M | 0.6% | 65 |
|
|
2022
Q3 | $15.9M | Sell |
257,416
-7,480
| -3% | -$472K | 0.83% | 49 |
|
|
2022
Q2 | $16.4M | Sell |
264,896
-115,836
| -30% | -$7.17M | 0.79% | 53 |
|
|
2022
Q1 | $22.6M | Sell |
380,732
-217
| -0.1% | -$13.9K | 0.91% | 45 |
|
|
2021
Q4 | $27.7M | Sell |
380,949
-20,136
| -5% | -$1.39M | 1.09% | 34 |
|
|
2021
Q3 | $28M | Buy |
401,085
+36,499
| +10% | +$2.56M | 1.18% | 31 |
|
|
2021
Q2 | $25.1M | Buy |
364,586
+2,053
| +0.6% | +$137K | 1.07% | 41 |
|
|
2021
Q1 | $23.4M | Buy |
362,533
+1,416
| +0.4% | +$91.3K | 1.06% | 39 |
|
|
2020
Q4 | $21M | Sell |
361,117
-18,722
| -5% | -$1.13M | 1.04% | 38 |
|
|
2020
Q3 | $24M | Sell |
379,839
-7,463
| -2% | -$518K | 1.33% | 28 |
|
|
2020
Q2 | $29.8M | Sell |
387,302
-103,518
| -21% | -$7.93M | 1.69% | 13 |
|
|
2020
Q1 | $36.7M | Sell |
490,820
-193,012
| -28% | -$13.3M | 2.23% | 10 |
|
|
2019
Q4 | $44.4M | Buy |
683,832
+101,863
| +18% | +$6.63M | 1.58% | 23 |
|
|
2019
Q3 | $36.9M | Sell |
581,969
-156,325
| -21% | -$10.2M | 1.41% | 30 |
|
|
2019
Q2 | $49.9M | Buy |
738,294
+5,935
| +0.8% | +$390K | 1.81% | 16 |
|
|
2019
Q1 | $47.6M | Buy |
732,359
+4,086
| +0.6% | +$272K | 1.76% | 13 |
|
|
2018
Q4 | $45.6M | Sell |
728,273
-20,585
| -3% | -$1.44M | 1.78% | 14 |
|
|
2018
Q3 | $57.8M | Sell |
748,858
-2,100
| -0.3% | -$159K | 1.84% | 11 |
|
|
2018
Q2 | $53.2M | Buy |
750,958
+18,918
| +3% | +$1.34M | 1.77% | 16 |
|
|
2018
Q1 | $55.2M | Buy |
732,040
+31,270
| +4% | +$2.49M | 1.83% | 16 |
|
|
2017
Q4 | $50.2M | Sell |
700,770
-2,239
| -0.3% | -$170K | 1.66% | 20 |
|
|
2017
Q3 | $57M | Buy |
703,009
+15,030
| +2% | +$1.15M | 1.96% | 8 |
|
|
2017
Q2 | $48.7M | Buy |
687,979
+141,560
| +26% | +$9.42M | 1.74% | 14 |
|
|
2017
Q1 | $37.1M | Buy |
+546,419
| New | +$38.4M | 1.35% | 36 |
|
Other funds holding GILD
VCM
VPM
Becker Capital Management's GILD Position: Q1 2026 in Review
Becker Capital Management reduced its Gilead Sciences (GILD) stake by 2.6% in Q1 2026, selling an estimated $23K and leaving 6,060 shares worth $845K. The position accounts for 0.02% of the portfolio, ranked #181.
Becker Capital Management first reported a position in GILD in Q1 2017 and has held it in 37 quarters since. The position peaked at $57.8M in Q3 2018. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.
- Becker Capital Management held 6,060 shares of Gilead Sciences worth $845K as of Q1 2026.
- Becker Capital Management sold 164 Gilead Sciences shares in Q1 2026, an estimated $23K.
- Gilead Sciences made up 0.02% of Becker Capital Management's portfolio in Q1 2026, its #181 holding.
- Becker Capital Management first reported a position in Gilead Sciences in Q1 2017 and has held it in 37 quarters since.
- Becker Capital Management's Gilead Sciences position peaked at $57.8M in Q3 2018.
- 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.
Based on Becker Capital Management's 13F filing for Q1 2026, filed 11 May 2026.